Steven H. Grossman

Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*

Ángel Crespo López, José A. Lorente, Jay S. Steingrub et al. · Critical Care Medicine · 2004 · 921 citations

Medicine, Pharmacology, Pharmacotherapy +13

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)

Christopher M. O’Connor, Wendy A. Gattis, Barry F. Uretsky et al. · American Heart Journal · 1999 · 518 citations

Medicine, Cardiology, Pharmacology +5

Unimolecular Micelles

George R. Newkome, Charles N. Moorefield, Gregory R. Baker et al. · Angewandte Chemie International Edition in English · 1991 · 383 citations

Natural Sciences, Chemistry, Polymer Chemistry +16

Administration of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)*

Jan Bakker, Robert F. Grover, Angela McLuckie et al. · Critical Care Medicine · 2004 · 196 citations

Medicine, Pharmacology, Pharmacotherapy +15

Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)*

David I. Watson, Robert F. Grover, Antonio Anzueto et al. · Critical Care Medicine · 2004 · 130 citations

Pharmacy, Pharmacology, Pharmacotherapy +15